drugset / Trial / NCT03974217
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study is testing if Talazoparib is an effective treatment for patients with AML and MDS that have a mutation in the cohesin complex.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2025-04-03
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | — | — |
| Subject | Talazoparib | Small molecule | — | Oral |